Evidence map›Paper›PMID 40351511›Full record

ArticleJournal of clinical tuberculosis and other mycobacterial diseases2025

Estimation of therapeutic threshold for tuberculosis using adapted nominal group technique and clinical vignettes in clinical and community settings in Southern Africa.

Alfred Kipyegon Keter, Alastair Van Heerden, Tom Decroo, Tom Boyles, Shannon Bosman, Thandanani Madonsela, Lindani Innocent Msimango, Lenika Naiken, Carlos Kiyan, Mashaete Kamele and 4 more

Abstract read
In one paragraph

Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alfred Kipyegon KeterInstitute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium.
Alastair Van HeerdenCenter for Community Based Research, Human Sciences Research Council, Pietermaritzburg, South Africa.
Tom DecrooInstitute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium.
Tom BoylesClinical HIV Research Unit, Helen Joseph Hospital, Johannesburg 2092, South Africa.
Shannon BosmanCenter for Community Based Research, Human Sciences Research Council, Pietermaritzburg, South Africa.
Thandanani MadonselaCenter for Community Based Research, Human Sciences Research Council, Pietermaritzburg, South Africa.
Lindani Innocent MsimangoCenter for Community Based Research, Human Sciences Research Council, Pietermaritzburg, South Africa.
Lenika NaikenCenter for Community Based Research, Human Sciences Research Council, Pietermaritzburg, South Africa.
Carlos KiyanInstitute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium.
Mashaete KameleSolidarMed Lesotho, Premium House, 224 Kingsway Street, Maseru, Lesotho.
Irene AyakakaSolidarMed Lesotho, Premium House, 224 Kingsway Street, Maseru, Lesotho.
Klaus ReitherSwiss Tropical and Public Health Institute, Kreuzstrasse 2, 4123 Allschwil, Switzerland.
Bart Karl Mario JacobsInstitute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium.
Lutgarde LynenInstitute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: When confronted with diagnostic uncertainty and a decision on whether to start treatment or not, clinicians consider the potential harm and benefit of offering versus withholding treatment. Treatment can be offered if the probability of tuberculosis (TB) in the patient is above the "therapeutic threshold" (ThT): the probability of disease at which the expected utility of treating and not treating is the same. We estimated ThT for TB in clinical and community settings in Southern Africa using two methods: an adapted nominal group technique (aNGT), and decisions made based on clinical vignettes (CVs). Methods: We enrolled health professionals involved in the routine management of TB patients in South Africa and Lesotho. The participants elicited, discussed and refined the harms of false positive (FP) and false negative (FN) treatment decisions for stable ambulatory patients in the clinical and community settings. They weighed all harms according to their importance in treatment decisions by distributing 100 points. ThT, calculated as the sum of the weights of the harms of the FP decision divided by the total weight, was estimated using a hierarchical Beta regression model. For the CVs, participants were presented with ten hypothetical TB cases in each setting and asked to indicate whether they would offer TB treatment or not. ThT was estimated using the generalized linear model for binary outcomes. Results: We enrolled 138 health professionals (aNGT: 123, CVs: 130 and 115 in both). Using aNGT, the overall ThT was 37.7% (95% credible intervals (95% CrI): 35.8-39.8) and 38.2% (95% CrI: 35.9-40.6) in the clinical and community settings, respectively. Compared to aNGT, CVs produced a significantly lower estimate in the clinical setting (27.7%; 95% CrI: 23.8-31.3) but similar in the community setting (37.7%; 95% CrI: 33.1-41.7). We did not find significant differences across the subgroups defined by the measured covariates. Conclusion: The aNGT produced a reliable estimate of ThT. The difference in the estimates of ThT between the aNGT and CVs may have a limited impact on clinical decisions. Factors influencing ThT and the acceptability of results by healthcare workers will be explored in focus group discussions and in-depth interviews.

Indexed as

Adapted nominal group techniqueClinical decision-makingClinical vignettesDiagnostic uncertaintyTherapeutic thresholdTuberculosis

Identifiers

PMID40351511
PMCPMC12063121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.